Valuation Picture: Premium Reflecting Sector Confidence
The current P/E of Sun Pharmaceutical Industries Ltd stands at 35.63, exceeding the Pharmaceuticals & Biotechnology sector average of 32.13. This premium suggests that investors are willing to pay more for the stock relative to its peers, potentially reflecting expectations of superior earnings growth or stability. However, the premium is moderate rather than extreme, indicating a balanced valuation environment. The market capitalisation of Rs 4,32,600 crores further cements its status as a large-cap stalwart within the sector.
Such a valuation premium often invites scrutiny — previously rated Hold, what is Sun Pharmaceutical Industries Ltd's current rating? The four-parameter analysis factors in this valuation alongside performance and technical indicators to provide a comprehensive view.
Performance Across Timeframes: A Tale of Contrasts
Examining the stock's returns reveals a compelling divergence between short and longer-term performance. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a positive return of 3.59%, outperforming the Sensex's negative 4.14% over the same period. This outperformance extends to the three-month timeframe, where the stock gained 4.42% compared to the Sensex's 12.52% decline, and year-to-date returns of 4.39% versus the Sensex's 12.70% fall.
Shorter-term momentum is also evident with a 1-month gain of 3.29% and a 1-week rise of 1.00%, both outperforming the Sensex. The stock has been on a two-day consecutive gain streak, rising 2.64% in that period, and is currently trading just 2.88% below its 52-week high of Rs 1850.95. The 1-day performance is essentially flat at 0.02%, in line with the sector's movement.
Longer-term returns paint a more mixed picture. Over three years, the stock has surged 82.45%, significantly outperforming the Sensex's 29.03%. The five-year return is even more impressive at 205.77% against the Sensex's 51.80%. However, the 10-year return of 112.05% trails the Sensex's 193.61%, indicating that while the stock has been a strong performer in recent years, it has lagged broader market gains over the last decade. Is this a sign of shifting sector dynamics or company-specific factors?
Moving Average Configuration: Bullish Momentum Confirmed
Technically, Sun Pharmaceutical Industries Ltd is trading above all key moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This configuration typically signals a strong bullish trend and suggests that recent price action is supported by sustained buying interest across multiple time horizons.
The stock's position above these averages also indicates a recovery or continuation of an upward trend rather than a breakdown or dead-cat bounce. This technical strength complements the positive short-term performance and may be a factor in the reassessment of the stock's rating. The 2.88% proximity to the 52-week high further underscores this momentum.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Sector Context: Mixed Results Amidst Pharmaceuticals & Biotechnology
The Pharmaceuticals & Biotechnology sector has seen varied results recently, with 32 stocks having declared results so far. Of these, 15 reported positive outcomes, 8 were flat, and 9 posted negative results. This distribution indicates a sector grappling with uneven performance, where Sun Pharmaceutical Industries Ltd appears to be holding its ground with steady gains and a valuation premium.
Such sector dynamics may influence investor sentiment and valuation multiples, making the stock's premium P/E ratio more understandable in the context of relative stability and growth prospects. Should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?
Rating Context: Previously Rated Hold, Now Reassessed
As of 23 Feb 2026, the rating for Sun Pharmaceutical Industries Ltd was updated from a previous Hold rating. The current Mojo Score stands at 72.0, reflecting a positive assessment based on valuation, performance, and technical factors. This reassessment aligns with the stock's recent outperformance relative to the Sensex and its strong technical positioning above key moving averages.
The rating update suggests a shift in the analytical view, factoring in the stock's premium valuation and sustained momentum. What is the current rating for Sun Pharmaceutical Industries Ltd following this reassessment?
Sun Pharmaceutical Industries Ltd caught your attention? Explore our comprehensive research report with in-depth analysis of this large-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth large-cap analysis
- - Valuation assessment included
Conclusion: Data Reflects a Balanced Yet Positive Outlook
The data for Sun Pharmaceutical Industries Ltd presents a nuanced picture. The stock trades at a modest premium to its sector P/E, signalling investor confidence tempered by valuation discipline. Its performance across multiple timeframes shows consistent outperformance relative to the Sensex, particularly in the short to medium term, supported by a robust technical setup above all major moving averages.
Sector results remain mixed, but the stock's resilience and recent rating reassessment from Hold to a more positive stance reflect its standing within the Pharmaceuticals & Biotechnology space. The combination of valuation, performance, and technical factors provides a comprehensive view of the stock's current position — should investors continue to hold, increase exposure, or reconsider their stance?
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
